HDL Cholesterol

Your HDL-C (high-density lipoprotein cholesterol) level is one of the most familiar numbers on a standard lipid panel, and for decades it has been called "good cholesterol." That label is not entirely wrong, but it is dangerously incomplete. A low HDL-C level reliably flags higher risk for heart disease, stroke, and heart failure. Yet the reverse does not hold the way most people assume: pushing HDL-C higher with drugs has never been shown to prevent heart attacks or save lives. Understanding what your number actually tells you, and what it does not, is one of the most important upgrades you can make to how you read your own lab work.

HDL-C measures the amount of cholesterol riding inside high-density lipoprotein particles in your blood. These particles ferry cholesterol away from artery walls back to the liver for recycling or disposal. That transport job is the reason HDL earned its "good" reputation. But the lab test counts only the cholesterol cargo, not how well the particles are actually doing their job. Two people with the same HDL-C number can have very different levels of real-world cardiovascular protection.

Why Higher Is Not Always Better

The most important thing to understand about HDL-C is the U-shaped curve. If you plot HDL-C levels against the risk of dying from any cause, the graph dips lowest in a middle range and rises on both sides. Very low levels are bad, as you would expect. But very high levels are also associated with increased risk of death, which most people find surprising.

In a large study of about 345,000 adults aged 20 to 79, people with HDL-C above 99 mg/dL had roughly 32% higher all-cause mortality compared to those in the moderate range (HR 1.32, 95% CI 1.21-1.43). The risk was not limited to heart disease. Cancer mortality was about 26% higher, and deaths from causes other than heart disease or cancer were about 68% higher in this very high HDL-C group. The elevated mortality was linked to conditions including alcoholic liver disease, alcohol-related cancers, and chronic lung disease.

What this means for you: if your HDL-C comes back very high, do not assume you have extra protection. It is worth a conversation with your clinician about possible drivers, especially alcohol intake or medications that raise HDL-C without improving its function.

A separate study of high-risk individuals confirmed a similar pattern. Among people who already had cardiovascular risk factors, those with HDL-C above 80 mg/dL (for men) or above 100 mg/dL (for women) showed increased rates of adverse cardiovascular outcomes. The traditional idea that you can never have too much "good cholesterol" does not hold up.

What Your Level Signals

Your HDL-C level is shaped heavily by genetics. Roughly 50 to 56% of the variation in HDL-C across people is inherited. That means your number is only partly a reflection of your habits. It is also a reflection of the genetic cards you were dealt, particularly in genes that control how cholesterol is transferred between particles and how the liver processes lipids.

Kidney function, inflammation, and metabolic health can all shift your result. Before interpreting any specific cutpoint, keep in mind that the same number can mean different things in different bodies. The ranges below come from large population studies, but your full clinical picture matters.

Sources: MESA study (Ahmed et al.); Park et al. cohort; Mørland et al. cohort; Liu et al. high-risk population study.

What this means for you: the sweet spot appears to be in the 40 to 60 mg/dL range for the lowest overall mortality risk. If your HDL-C is below 40, that is a meaningful signal of elevated cardiovascular risk, especially if your other lipid numbers are also unfavorable. If your HDL-C is above 80 or 90, it deserves the same scrutiny you would give an abnormally low result.

Importantly, HDL-C retains predictive value even if you are already on a statin and your LDL cholesterol is very low. In a pooled analysis of statin-treated individuals, those with lower HDL-C still experienced more cardiovascular events than those with higher HDL-C, regardless of how low their LDL-C went. So HDL-C adds information on top of what LDL-C tells you.

The Disconnect Between Raising HDL-C and Reducing Risk

Here is the puzzle that has reshaped how researchers think about HDL. In randomized trials, drugs that raise HDL-C, including niacin, fibrates, and a class of drugs called CETP inhibitors, have consistently failed to reduce heart attacks or cardiovascular deaths when added to statin therapy. If HDL-C were directly protective, raising it should help. It does not.

Genetic evidence points in the same direction. A technique called Mendelian randomization uses naturally occurring gene variants as a kind of lifelong experiment. People who carry gene variants that give them higher HDL-C from birth do not end up with less coronary artery disease, once you account for the effects of those same genes on other lipid pathways. In other words, the gene variants raise HDL-C, but that rise does not translate into protection.

This has led researchers to conclude that HDL-C is most likely a marker of cardiovascular risk rather than a cause of protection. Think of it like a thermometer: it tells you something important is happening, but changing the reading on the thermometer does not change the underlying temperature. The focus is now shifting to HDL function, particularly a measure called cholesterol efflux capacity, which quantifies how effectively your HDL particles pull cholesterol out of artery walls. Early research suggests this functional measure correlates more strongly with cardiovascular outcomes than HDL-C alone.

What Moves This Biomarker

Even though raising HDL-C with drugs has not reduced cardiovascular events, the lifestyle factors that raise HDL-C are still worth pursuing. They improve cardiovascular health through multiple pathways beyond HDL-C itself, including reduced inflammation, better blood vessel function, and improved HDL particle quality.

Aerobic exercise: Regular aerobic exercise raises HDL-C by about 2 to 5 mg/dL (roughly 5 to 9%) in sedentary individuals. The key variable is how long each session lasts, not how hard you push. Every additional 10 minutes of exercise per session corresponds to roughly a 1.4 mg/dL increase. You need at least 120 minutes per week to see meaningful changes. A meta-analysis of 42 trials found that aerobic exercise significantly improved HDL-C, while resistance training and stretching did not. Changes may appear within 8 weeks, though some people need longer. Aim for five sessions of about 30 minutes of brisk activity per week.

Smoking cessation: Quitting smoking raises HDL-C by about 4 mg/dL, with favorable changes detectable as early as 30 days after quitting. Smokers tend to have about 9% lower HDL-C than nonsmokers, with a dose-dependent effect.

Weight loss: Once you reach a stable lower weight, expect HDL-C to rise by about 0.35 mg/dL for every kilogram lost. There is an important nuance here: during active weight loss, HDL-C may temporarily drop before it rises. In one trial, people who exercised but did not lose weight saw no HDL-C improvement, suggesting that the weight loss itself may be the more important lever.

Alcohol: Moderate intake (roughly 1 to 3 drinks per day) can raise HDL-C by up to 12%. In a cohort study of adults undergoing annual checkups, initiating 1.5 to 3 drinks per day raised HDL-C by about 2.5 mg/dL, and more than 3 drinks per day raised it by about 6 mg/dL. However, stopping alcohol led to decreases of 1 to 6 mg/dL depending on prior intake. Current guidelines recommend no more than 2 drinks per day for men and 1 for women. If you do not drink, the overall health risks of alcohol outweigh any HDL-C benefit, and you should not start.

Dietary changes: Replacing saturated and trans fats with monounsaturated and polyunsaturated fats (from sources like olive oil, nuts, and fish) can improve the ratio of LDL-C to HDL-C and may enhance HDL's anti-inflammatory properties. Increasing omega-3 fatty acids from fish and marine oils is associated with higher HDL-C. Mediterranean and DASH style eating patterns are recommended for improving lipid profiles broadly.

Medications: No drug is currently recommended specifically to raise HDL-C as a treatment target. Niacin, fibrates, and CETP inhibitors all raise HDL-C but have not reduced cardiovascular events in randomized trials when added to statin therapy. Current guidelines do not set an HDL-C target for pharmacological treatment.

Questions This Biomarker Can Answer

• Is my cardiovascular risk higher than my LDL cholesterol alone would suggest?
• Is my very high HDL-C actually a reason for concern rather than reassurance?
• Are my exercise habits and dietary changes meaningfully shifting my lipid profile?
• Do I have isolated low HDL-C that puts me in a higher-risk category even if my other lipids look normal?
• Is my HDL-C in the range associated with the lowest overall mortality?